Stingray Reports Third Quarter Results for Fiscal 2023 8-02-2023, 06:04

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Mediheal chọn MINNIE (G)I-DLE làm người mẫu thương hiệu toàn cầu! 27-06-2024, 14:51